24–25 Nov 2026
IARC
Europe/Paris timezone

Cost-effectiveness models of lung cancer screening by LDCT in Europe from 2015 to 2026: a systematic review and methodological assessment adapted for France

T2-1
25 Nov 2026, 09:45
15m
RC 150 - Auditorium (IARC)

RC 150 - Auditorium

IARC

25 avenue Tony Garnier, Lyon, France
Extended oral Cancer Screening, Early Detection & Health Systems Cancer Screening, Early Detection & Health Systems

Speaker

Lucie Simon (Université Lyon 1, Inserm U1290 Research on Healthcare Performance (RESHAPE), Lyon, France)

Description

INTRODUCTION: Low-dose CT screening (LDCT) reduces lung cancer mortality by detecting tumours at earlier, more treatable stages, but implementing it is costly. Before France's pilot programme, IMPULSION, is extended nationwide, its efficiency needs to be established. We conducted a systematic review of European cost-effectiveness models of lung cancer screening, with methodological assessments, to identify elements relevant to a future French model.
METHODS: We searched PubMed, Embase and Cochrane (2015–2026) for European decision-analytic models evaluating the cost-effectiveness of LDCT screening. Study selection, quality assessment and data extraction, including incremental cost-effectiveness ratio (ICER) in euros per quality-adjusted life years (QALY), were performed independently by two reviewers.
RESULTS: Twenty-one studies from 14 European countries were included. ICER varied between 2,345-50,000€/QALY gained, median 11,487€, but studies rarely accounted for the same costs. Scan, diagnosis and treatment costs were included everytime, but only 66% of studies included recruitment costs (invitations, phone calls) and 24% included organisational costs (communication, infrastructure), despite their influence on real-world feasibility. Participation rates also varied widely across models (25–100%) but were rarely tested in sensitivity analyses. Costs of innovative treatment (immunotherapies/targeted therapies) were included in only 67% of studies whereas most are less than 10 years old.
CONCLUSION: These findings confirm that LDCT screening is generally cost-effective with ICERs < 50,000€/QALY, a threshold commonly considered acceptable, in populations comparable to IMPULSION's. They also highlight two under-explored determinants for a future French model: organisational costs and real-world participation, both critical to assessing the feasibility of nationwide screening in France.

Author

Lucie Simon (Université Lyon 1, Inserm U1290 Research on Healthcare Performance (RESHAPE), Lyon, France)

Co-authors

Emmanuel Grolleau (Université Lyon 1, Inserm U1290 Research on Healthcare Performance (RESHAPE), Lyon, France) Francois-Emery Cotte (Bristol Myers Squibb, HEOR, Rueil-Malmaison, France) Isabelle Durand-Zaleski (URCEco, Hôpital Hôtel Dieu, AP-HP, Paris, France) Sebastien Couraud (Université Lyon 1, Inserm U1290 Research on Healthcare Performance (RESHAPE), Lyon, France)

Presentation materials

There are no materials yet.